Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Account Payables (2016 - 2026)

Spyre Therapeutics' Change in Account Payables history spans 11 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 208.29% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $8.2 million, up 3681.74%, while the annual FY2025 figure was $8.2 million, 3681.74% up from the prior year.
  • Change in Account Payables reached $4.9 million in Q4 2025 per SYRE's latest filing, up from $321000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.9 million in Q4 2025 to a low of -$4.5 million in Q4 2024.
  • Average Change in Account Payables over 5 years is $212105.3, with a median of $125000.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: skyrocketed 29200.0% in 2021, then crashed 1467.25% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $1.5 million in 2021, then crashed by 340.55% to -$3.5 million in 2022, then surged by 91.8% to -$287000.0 in 2023, then plummeted by 1467.25% to -$4.5 million in 2024, then skyrocketed by 208.29% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Change in Account Payables are $4.9 million (Q4 2025), $321000.0 (Q3 2025), and $23000.0 (Q2 2025).